Comparing Ultragenyx Pharmaceutical (RARE) and Its Competitors
Ultragenyx Pharmaceutical (NASDAQ: RARE) is one of 296 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its peers? We will compare Ultragenyx Pharmaceutical to similar businesses based on the strength of its profitability, valuation, risk, earnings, institutional ownership, analyst recommendations and dividends.
This is a breakdown of current ratings for Ultragenyx Pharmaceutical and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Ultragenyx Pharmaceutical Competitors||765||3041||11224||227||2.72|
Ultragenyx Pharmaceutical currently has a consensus price target of $71.94, suggesting a potential upside of 59.19%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 35.83%. Given Ultragenyx Pharmaceutical’s higher probable upside, analysts plainly believe Ultragenyx Pharmaceutical is more favorable than its peers.
Volatility & Risk
Ultragenyx Pharmaceutical has a beta of 1.89, indicating that its share price is 89% more volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical’s peers have a beta of 6.62, indicating that their average share price is 562% more volatile than the S&P 500.
Insider & Institutional Ownership
96.2% of Ultragenyx Pharmaceutical shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 9.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Comparatively, 16.4% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Ultragenyx Pharmaceutical and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Ultragenyx Pharmaceutical||$115,999.00||-$280.32 million||-6.70|
|Ultragenyx Pharmaceutical Competitors||$260.16 million||$66.28 million||-6.36|
Ultragenyx Pharmaceutical’s peers have higher revenue and earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This table compares Ultragenyx Pharmaceutical and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Ultragenyx Pharmaceutical Competitors||-5,489.25%||-451.68%||-42.65%|
Ultragenyx Pharmaceutical peers beat Ultragenyx Pharmaceutical on 8 of the 12 factors compared.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies. Its product candidates under biologics category include KRN23 (UX023) and recombinant human beta-glucuronidase (rhGUS) (UX003). Its product candidates under small-molecule category include UX007 and aceneuramic acid extended-release (Ace-ER) (UX001). It is also developing recombinant human protective protein cathepsin-A (rhPPCA). KRN23 is a fully human monoclonal antibody. rhGUS is an intravenous (IV) enzyme replacement therapy. UX007 is a substrate replacement therapy. It is developing Ace-ER for the treatment of GNE myopathy. rhPPCA is in preclinical development.
Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.